NBI‑921352 (formerly known as XEN901) is a highly selective sodium channel inhibitor targeting the Na_V1.6 subtype, designed with a precision-medicine approach for treating certain seizure disorders, especially SCN8A-related epilepsies. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Zandatrigine and Zandatrigina. Its PubChem CID is 132141687.
Nbi-921352
| CAS No | 2154406-04-7 |
|---|---|
| Molecular Formula | C22H25FN4O2S2 |
| Molecular Weight | 460.6 g/mol |
| Synonyms | 4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
6 subtype, designed with a precision-medicine approach for treating certain seizure disorders, especially SCN8A-related epilepsies. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin.
The listed CAS number is 2154406-04-7.
The listed molecular formula is C22H25FN4O2S2.
The listed molecular weight is 460.6 g/mol.
4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide.
The source lists Zandatrigine and Zandatrigina.